August 24, 2016 09:11 AM EDTUpdated June 28, 12:35 PM
Bioregnum
Opinion

BioReg­num: The mob is back. And what's to stop them from go­ing af­ter the en­tire bio­phar­ma in­dus­try?

My­lan to­day is at the cen­ter of the lat­est on­line mael­strom to erupt over drug pric­ing and ac­cess to ther­a­pies. And while it …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

SV Health’s $269M de­men­tia fund; Schrödinger lays off 7% of staff

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

GSK kicks off Blenrep re­launch plans with clear­ance from UK reg­u­la­tors

Ge­of­frey Porges ex­its Schrödinger with CFO swap; A new board seat for As­traZeneca's Pas­cal So­ri­ot

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times